Navigation Links
Neuralstem Responds to New StemCells, Inc. Lawsuit
Date:5/12/2008

ROCKVILLE, Md., May 12 /PRNewswire-FirstCall/ -- Stem cell company Neuralstem, Inc. (Amex: CUR) responded today to the two new patent infringement suits filed against it Friday by StemCells, Inc., saying that it believes them, and the earlier claims by StemCells, Inc. against the company, to be baseless.

(Logo: http://www.newscom.com/cgi-bin/prnh/20061221/DCTH007LOGO )

"As we alleged in the counterclaim to their lawsuit, which we filed in October, 2006, StemCells, Inc. has engaged in a pattern of harassment and anti-competitive behavior," said Neuralstem CEO and President, Richard Garr. "This is what we have come to expect from StemCells, Inc. and we believe these new suits are entirely consistent with its past strategy."

"The other interesting point of today's press release is that StemCells, Inc., is now backing off of its promise, made publicly in a press release not long ago, to expeditiously re-open its original infringement suit against us," Garr continued. "In fact, Neuralstem moved to re-open that suit, so that it could move for summary judgment based upon the Patent Office's recent actions. To us, it sounds like StemCells, Inc. is now trying to make an excuse for arguing against re-opening that case. We are not surprised. As we said earlier, we believe that actions of the Patent Office have destroyed the basis for those infringement assertions against us."

About Neuralstem

Neuralstem's patented technology enables, for the first time, the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells into mature, physiologically relevant human neurons and glia.

Major Central Nervous System diseases targeted by the Company with research programs currently underway include: Ischemic Paraplegia, Traumatic Spinal Cord Injury and ALS. The company's cells have extended the life of rats with ALS (Lou Gehrig's disease) as reported the journal TRANSPLANTATION, in collaboration with Johns Hopkins University researchers, and also reversed paralysis in rats with Ischemic Spastic Paraplegia, as reported in NEUROSCIENCE on June 29, 2007, in collaboration with researchers at University of California San Diego.

The company has also developed immortalized human neural stem cells for in-vitro use in drug development for the academic and pharmaceutical markets. For further information, please visit http://www.neuralstem.com.

Cautionary Statement Regarding Forward Looking Information

This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Neuralstem's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward- looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem's periodic reports, including the quarterly report on Form 10-KSB for the year ended December 31, 2007.


'/>"/>
SOURCE Neuralstem, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Neuralstem Sues StemCells, Inc. Over New Patent
2. Neuralstem Inc. Announces Strategic Investment by Korean CJ CheilJedang Corporation
3. Patent Office Rules in Neuralstems Favor in Dispute with StemCells, Inc.
4. American Stock Exchange Lists The Common Stock Of Neuralstem, Inc.
5. Neuralstem Shares Accepted for Trading on Amex(R)
6. AGA Medical Corporation Responds to Occlutech Statement on the Status of the Ongoing Patent Litigation in Europe
7. MichBio Responds to Governors Plan to Repeal Tort Reform Laws
8. CellCyte Genetics Corp. Responds to Plaintiff Law Firm Press Releases
9. Bio-Identical Hormone Menopause Doctor Responds to Recent FDA News About Estriol
10. Bio-Identical Hormone Menopause Doctor Responds to Outrageous FDA News
11. CryoLife Responds to Inaccurate Assertions from Plaintiffs Attorney
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2017)... ... April 27, 2017 , ... ... why mass flow controllers based on capillary thermal mass flow technology provide exponentially ... flow control applications. Over 80% of all industrial processes—such as those involving ...
(Date:4/27/2017)... ... 27, 2017 , ... The Council for Agricultural Science and ... Lusk, a consummate communicator who promotes agricultural science and technology in the public ... explains how innovation and growth in agriculture are critical for food security and ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... premiere team-building and cooking events company, offers one-of-a-kind gifts, ranging from gourmet cooking ... in California cuisine, and guests leave inspired with new cooking tips and techniques, ...
(Date:4/26/2017)... ... April 25, 2017 , ... LABS, Inc. (LABS) announced in December 2016 ... extensive test menu: Nucleic Acid Testing (NAT) for ZIKV; and Enzyme Immunoassays (EIAs) specific ... offer NAT screening for blood donors under an Investigational New Drug (IND) study protocol. ...
Breaking Biology Technology:
(Date:3/30/2017)... The research team of The Hong Kong ... identification by adopting ground breaking 3D fingerprint minutiae recovery and matching ... and accuracy for use in identification, crime investigation, immigration control, security ... ... A research team led by ...
(Date:3/28/2017)... PUNE, India , March 28, 2017 ... (Analog, IP, Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), ... Maintenance), Vertical, and Region - Global Forecast to 2022", ... 30.37 Billion in 2016 and is projected to reach ... 15.4% between 2017 and 2022. The base year considered ...
(Date:3/24/2017)... 24, 2017 Research and Markets has announced ... Analysis & Trends - Industry Forecast to 2025" report to ... The ... a CAGR of around 15.1% over the next decade to reach ... analyzes the market estimates and forecasts for all the given segments ...
Breaking Biology News(10 mins):